{"id":295,"date":"2025-01-28T10:28:38","date_gmt":"2025-01-28T01:28:38","guid":{"rendered":"http:\/\/evermed.jp\/?p=295"},"modified":"2025-01-28T10:29:18","modified_gmt":"2025-01-28T01:29:18","slug":"evermed-inc-received-investment-from-nissay-capital-co-ltd-as-the-final-closing-of-its-seed-round-%e3%80%80","status":"publish","type":"post","link":"http:\/\/evermed.jp\/?p=295","title":{"rendered":"EVerMed Inc. received investment from NISSAY CAPITAL CO.,LTD. as the final\u00a0closing of its seed round.\u3000"},"content":{"rendered":"\n<p class=\"has-text-align-right wp-block-paragraph\">January 28, 2024<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">EVerMed Inc. has raised 180 million yen through a third-party allotment of new shares to Nissay Capital No. 13 Investment Limited Partnership (Chiyoda-ku, Tokyo; General Partner: NISSAY CAPITAL CO.,LTD., President and CEO Kosuke Ueda ) .<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">EVerMed is a startup company originating from the Jikei University School of Medicine that aims to apply extracellular vesicles to medical applications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Including this capital increase, the total amount raised in the seed round has reached approximately 510 million yen.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We are currently developing bronchial epithelial cell-derived extracellular vesicles (EM-001) for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary fibroblast-derived extracellular vesicles (EM-002) for the treatment of COPD and are also developing &nbsp;technologies to create new pipelines.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>January 28, 2024 EVerMed Inc. has raised 180 million yen through a third-party allotment of new shares to Nissay Capital No. 13 Investment Limited Partnership (Chiyoda-ku, Tokyo; General Partner: NISSAY CAPITAL CO.,LTD., President and CEO Kosuke Ueda ) . EVerMed is a startup company originating from the Jikei University School [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-295","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"http:\/\/evermed.jp\/index.php?rest_route=\/wp\/v2\/posts\/295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/evermed.jp\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/evermed.jp\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/evermed.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/evermed.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=295"}],"version-history":[{"count":1,"href":"http:\/\/evermed.jp\/index.php?rest_route=\/wp\/v2\/posts\/295\/revisions"}],"predecessor-version":[{"id":296,"href":"http:\/\/evermed.jp\/index.php?rest_route=\/wp\/v2\/posts\/295\/revisions\/296"}],"wp:attachment":[{"href":"http:\/\/evermed.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/evermed.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=295"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/evermed.jp\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}